Omicron XBB-adapted COVID-19 vaccine

Omicron XBB-adapted COVID-19 vaccines are updated formulations of COVID-19 vaccines designed to provide protection against the Omicron XBB sublineages of SARS-CoV-2, particularly XBB.1.5. These vaccines, which include both mRNA-based and protein-based platforms, work by presenting the immune system with genetic material or protein subunits corresponding to the spike protein of the XBB variant. This triggers the body to produce neutralizing antibodies and T-cells, thereby enhancing immunity and reducing the risk of infection and severe disease. Developed by companies like Pfizer/BioNTech, Moderna, and HIPRA, these vaccines were introduced in response to the continuous evolution of the SARS-CoV-2 virus and the emergence of variants capable of evading prior immunity. They have received regulatory approvals and authorizations in various regions, including the United States and the European Union, for individuals typically aged 6 months and older.

Brand names

COMIRNATY Omicron XBB.1.5Spikevax

Other names

monovalent XBB.1.5-adapted mRNA vaccinesupdated COVID-19 vaccine